Neurolathyrism

Definition

Causative Agent / Neurotoxin

• BOAA over-stimulates AMPA glutamate receptors
• Leads to increased intracellular reactive oxygen species (ROS)
• Impairs mitochondrial oxidative phosphorylation
• Causes selective degeneration of Betz cells in the motor cortex and the longest corticospinal tracts subserving lower-limb function
• Anterior horn cells are spared

Epidemiology (Community Medicine Perspective)

Clinical Features

• Pain, paresthesias (formications/tingling), and weakness in the lower extremities
• Progressive spastic paraplegia (bilateral)
• Leg cramps and spasms
• Bladder dysfunction — frequency, urgency, sphincteric spasms
• Erectile dysfunction
• Occasional coarse tremor of upper extremities

• Predominantly upper motor neuron signs (spasticity, hyperreflexia, extensor plantar response)
• Sensation is usually preserved (though some historical cases reported sensory loss)
• Once established, the disorder is irreversible but non-progressive (unless exposure continues)
• Lifespan is not affected

Neuropathology

• Degeneration of corticospinal tracts and posterior columns in the spinal cord
• Loss of myelinated fibers in lateral and posterior columns
• Loss of large Betz cells in motor cortex
• Anterior horn cells are unaffected (distinguishing from ALS/polio)
• Gliosis and thickening of blood vessel walls in degenerated tracts

Prevention (Community Medicine Focus)

Differential Diagnosis

• Konzo (cyanide toxicity from cassava — similar UMN picture)
• Tropical spastic paraparesis (HTLV-I)
• Hereditary spastic paraplegia
• Primary lateral sclerosis
• Spinal cord compression

Key Points for Exams

• Cause: BOAA toxin in Lathyrus sativus (grass pea / khesari dal)
• Mechanism: Excitotoxicity via AMPA receptor over-activation
• Pathology: Upper motor neuron disease; Betz cells degenerate; anterior horn cells spared
• Features: Irreversible spastic paraplegia, no sensory loss typically, non-progressive
• Occurs during famines/droughts — a classic community medicine/public health topic
• Prevention: Dietary diversification, detoxification of peas before consumption

Natural History of Disease

(As per K. Park — Preventive & Social Medicine)

Definition

Two Periods in Natural History of Disease

1. Pre-pathogenesis Period

• The ecological triad (Agent – Host – Environment) is in equilibrium or being disturbed
• The host is susceptible but not yet diseased
• The appropriate intervention here is Primary Prevention

2. Pathogenesis Period

a) Early Pathogenesis (Sub-clinical / Pre-symptomatic)

• Biological/pathological changes are occurring
• No signs or symptoms yet detectable clinically
• May be detectable by screening tests
• Appropriate intervention: Secondary Prevention (early diagnosis and treatment)

b) Late Pathogenesis (Clinical Disease)

• Symptoms and signs become manifest
• Can progress to:
  • Recovery
  • Disability
  • Death

Leavell & Clark's Model: Levels of Prevention

Primary Prevention

• Health education
• Adequate nutrition
• Provision of adequate housing, recreation, working conditions
• Marriage counselling and sex education
• Attention to personality development
• Genetic counselling

• Immunisation against specific diseases
• Use of specific nutrients (e.g. iodine in salt for goitre)
• Protection from occupational hazards
• Protection from accidents
• Use of specific nutrients (vitamins)
• Environmental sanitation
• Protection from carcinogens

Secondary Prevention

• Case-finding surveys (mass/selective screening)
• Screening and follow-up
• Objectives: cure, prevent spread, prevent complications

• Adequate treatment to prevent disability (applied in late pathogenesis)
• Provision of facilities to limit disability

Tertiary Prevention

• Medical rehabilitation (maximum physical capacity)
• Social rehabilitation (restore social functioning)
• Vocational rehabilitation (gainful employment)
• Psychological rehabilitation

Concept of the "Iceberg of Disease"

        /\        ← Clinical cases (visible above waterline)
       /  \
      /    \
─────────────────  ← Waterline (clinical threshold)
    /        \
   /   Sub-    \
  /   clinical  \   ← Undiagnosed / sub-clinical cases (below waterline)
 /  Susceptibles \
/________________\  ← Susceptibles

• The tip of the iceberg = symptomatic/diagnosed cases (what clinicians see)
• The submerged portion = sub-clinical infections, undiagnosed cases, carriers, and susceptibles
• This "hidden" mass is the reservoir from which clinical cases emerge
• Screening programs aim to detect sub-clinical disease before it surfaces

Spectrum of Disease

• Agent factors (virulence, pathogenicity, dose)
• Host factors (immunity, nutrition, genetics)
• Environmental factors

Significance in Community Medicine

1. Identifies the right point for intervention at each stage
2. Guides screening program design (targeting sub-clinical disease)
3. Explains why prevention is better than cure — intervening early (pre-pathogenesis) is most effective
4. Forms the basis of the Leavell & Clark triad of prevention
5. Helps estimate true disease burden (iceberg concept)
6. Informs the design of health education messages

Note: K. Park's "Textbook of Preventive and Social Medicine" is not available in this library's collection. This answer is compiled from the established content of that text as it appears in the standard community medicine curriculum, cross-referenced with principles from Harrison's, Goldman-Cecil, and Family Medicine textbooks available in the library.

Screening of Diseases

(Community Medicine / Preventive Medicine — K. Park Framework)

Definition

A screening test is not diagnostic — it identifies suspects who require further definitive investigation.

Purpose / Objectives

• Early detection of disease in its pre-symptomatic phase (secondary prevention)
• Reduce morbidity and mortality from disease
• Identify high-risk individuals for targeted intervention
• Estimate the prevalence of a condition in a community

Types of Screening

Wilson & Jungner Criteria (WHO, 1968)

"Principles of Screening"

1. The condition should be an important health problem
2. There should be an accepted treatment for patients with the disease
3. Facilities for diagnosis and treatment should be available
4. There should be a recognisable latent or early symptomatic stage
5. There should be a suitable test or examination for the disease
6. The test should be acceptable to the population
7. The natural history of the disease should be adequately understood
8. There should be an agreed policy on whom to treat
9. The cost of case-finding (including diagnosis and treatment) should be economically balanced in relation to possible expenditure on medical care as a whole
10. Case-finding should be a continuous process and not a once-and-for-all project

Validity of a Screening Test

                  Disease PRESENT   Disease ABSENT
Test POSITIVE          a (TP)           b (FP)
Test NEGATIVE          c (FN)           d (TN)

• Sensitivity and specificity are relatively independent of prevalence
• PPV and NPV are strongly dependent on prevalence (disease frequency in the population)
• High prevalence → higher PPV for the same sensitivity/specificity
• Screening is most efficient when disease prevalence is high in the target population

Trade-off: Sensitivity vs Specificity

• Lowering the cut-off → ↑ Sensitivity, ↓ Specificity (more FP, fewer FN)
• Raising the cut-off → ↑ Specificity, ↓ Sensitivity (fewer FP, more FN)
• Ideal test: High sensitivity + High specificity

Reliability (Reproducibility) of a Screening Test

• Observer variation (intra-observer and inter-observer)
• Biological variation in the subject
• Test methodology/equipment variation

Yield of Screening

• Prevalence of unrecognised disease
• Sensitivity of the test
• The proportion of the population that agrees to be screened
• Number of previously screened individuals in the group

Biases in Screening

Harms of Screening

• False-positive results → unnecessary anxiety, further invasive tests
• False-negative results → false reassurance, delayed diagnosis
• Overdiagnosis → unnecessary treatment with attendant side effects
• Radiation exposure (mammography, CT)
• Psychological harm (anxiety during the screening process)

Evaluation of a Screening Programme

1. Does it reduce cause-specific mortality (not just survival)?
2. What is the number needed to screen (NNS) to prevent one death?
3. What is the gain in average life expectancy for the population?

Example: 731 women aged 65–69 must be screened by DEXA (and treated appropriately) to prevent one hip fracture from osteoporosis. — Harrison's, 22nd Ed.

Examples of Common Screening Programmes

Screening vs Diagnosis

Key Formulas Summary

Sensitivity    = TP / (TP + FN)  × 100
Specificity    = TN / (TN + FP)  × 100
PPV            = TP / (TP + FP)  × 100
NPV            = TN / (TN + FN)  × 100

False Positive Rate = FP / (FP + TN) = 1 − Specificity
False Negative Rate = FN / (FN + TP) = 1 − Sensitivity